H. Lundbeck A/S (LON:0ND5)
London
· Delayed Price · Currency is GBP · Price in DKK | Market Cap | 3.88B |
| Revenue (ttm) | 2.57B |
| Net Income (ttm) | 368.84M |
| Shares Out | n/a |
| EPS (ttm) | 0.37 |
| PE Ratio | 10.52 |
| Forward PE | 6.58 |
| Dividend | 0.11 (0.30%) |
| Ex-Dividend Date | Mar 27, 2025 |
| Volume | 16,146 |
| Average Volume | 12,992 |
| Open | 34.72 |
| Previous Close | 34.32 |
| Day's Range | 34.54 - 35.84 |
| 52-Week Range | 27.20 - 49.38 |
| Beta | n/a |
| RSI | 47.17 |
| Earnings Date | Aug 20, 2025 |
About H. Lundbeck
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomati... [Read more]
Financial Performance
In 2024, H. Lundbeck's revenue was 22.00 billion, an increase of 10.51% compared to the previous year's 19.91 billion. Earnings were 3.14 billion, an increase of 37.25%.
Financial numbers in DKK Financial StatementsNews
New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine
The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated statistically significant reduction...
New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine
The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically significant reduct...
Lundbeck Delivering On The Financials, But Needs Some Positive Clinical Drivers
Lundbeck's shares have declined due to U.S. policy risks and a perceived clinical setback, but core financial performance remains strong with solid Q1 results. Near-term upside hinges on regulatory su...
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
VALBY, Denmark , March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a po...
Lundbeck's Appreciation Potential Is Closely Tied To A High-Risk Clinical Pipeline (Rating Upgrade)
Lundbeck’s drug portfolio faces patent expirations but shows growth potential. Find out why HLBBF stock could see upside with successful clinical trials.